In January I have hightlighted CORDLIFE a potential muti-baggers when it was trading below 60 cents. Lately it's trading as high as $1.185, doubling it prices. It's look like it's finding support and consolidate it gain. At this level it's pricing closer to the rest of the healthcare stocks.
I still like this stock becuse of high profit margin, resilence business, positive cash flow, debt free and the potential growth come from the newly acquire Cord Blood & Cord Tissue Banking Business & Assets in Philippines, Indonesia, India & Hong Kong. Cordlife future looks promising.
Cordlife is still my core stocks.
Similarly like Observer2, I've sold the excess shares bought for good profit.
As long as Cordlife growth & profit margin is on track, I will hold onto it. Even thought it has double it price, it's PE is still the loweest among the health-care stocks. Comparatively Cordlife have better growth potential thenthe other more establish health-care stocks.
Catching the early growth stage of a company are the most rewarding because it's usually the cheaper before it's fully price in but the risk may be higher than the more establishing company.